Anti-Carbamylated antibodies as a marker of activity and disability in Rheumatoid Arthritis | ||||
| Minia Journal of Medical Research | ||||
| Volume 31, Issue 4, October 2020, Page 6-12 PDF (209.56 K) | ||||
| DOI: 10.21608/mjmr.2022.214419 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed E. Hafez; Aya H. Abdelazeem; Ayman F. Darwesh | ||||
| Department of Rheumatism, El-Minia Faculty of Medicine | ||||
| Abstract | ||||
| Objective: To investigate whether serum levels of anti-Carbamylated antibodies are specifically elevated in active rheumatoid arthritis compared to clinical and laboratory markers of disease activity. Methods: Sixty rheumatoid arthritis patients according to the ACR-EULAR criteria 2010 and 30 matched healthy controls were recruited. Clinical evaluation of disease activity was measured by; morning stiffness duration, Visual analogue scale, number of tender joints, number of swollen joints and DAS-28. Functional assessment was measured by the health assessment questionnaire (HAQ). Laboratory measures; ESR, CRP and RF titer was also done and finally radiological activity by ultrasound 7 score were determined parallel and correlated. Results: anti-Carbamylated antibody was found to be positive in more than 50% of patients with active RA. Those patients were seronegative for RF. Anti-Carbamylated antibody positivity was significantly associated with duration of morning stiffness, number of tender joints, number of swollen joints, DAS28, HAQ DI, and acute phase reactants (ESR & CRP). Conclusion: Anti-CarP antibody was found to be positive in RA patients and it was significantly correlated with clinical, laboratory and radiological markers of disease activity as well as the functional assessment. | ||||
| Keywords | ||||
| Rheumatoid Arthritis; Anti-Carbamylated; antibodies | ||||
|
Statistics Article View: 79 PDF Download: 126 |
||||
